Industry

The Phase 2 trial for the treatment of NASH met its primary efficacy endpoint; PXL065-treated patients achieved statistically significant improvements in the relative decrease in liver fat content measured by magnetic resonance imaging estimated proton density fat fraction (MRI-PDFF) at 36-weeks for all doses. Key secondary measures in PXL065-treated patients included a statistically significant improvement … [Read more…]

BEIJING & SAN DIEGO–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment … [Read more…]

BEIJING & SAN DIEGO–(BUSINESS WIRE)–#Biocytogen–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment … [Read more…]

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, confirms that the Ontario Securities Commission (the “OSC”) has issued a failure to file cease trade order against the Company (“FTFCTO”) which orders that general trading, whether direct or indirect, by any person, of … [Read more…]

94 percent of MultiPlan employees say that people of all cultures, abilities, and backgrounds are respected and valued at MultiPlan NEW YORK–(BUSINESS WIRE)–$MPLN #MPLN—MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”), a market-leading, technology-enabled provider of end-to-end healthcare cost management solutions, announced today its designation as a Great Place to Work-Certified™ company for 2022-2023. This distinction … [Read more…]

P3 Nevada Acquires Pahrump Cardiology & Family Practice PAHRUMP, Nev.–(BUSINESS WIRE)–P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that P3 Health Partners-Nevada, LLC (“P3 Nevada”) is expanding its footprint in Nye County with the recent acquisition of a cardiology and multi-specialty practice. Pahrump Cardiology & Family … [Read more…]

MUMBAI, India–(BUSINESS WIRE)–#asia–Anuva (formerly known as Global Gene Corp) enters into its next stage of growth focused on creating the most diverse Genomic Bio / Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States. Anuva … [Read more…]

AUSTIN, Texas–(BUSINESS WIRE)–agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health in our communities, announced that it will participate in the following investor conferences: The 2022 Wells Fargo Healthcare Conference, including a fireside chat presentation on Thursday, September 8 at 10:25 AM Eastern Time. The Morgan Stanley 20th Annual Global Healthcare … [Read more…]

SANTA MONICA, Calif.–(BUSINESS WIRE)–GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced that executives from the Company will be presenting at the Goldman Sachs 2022 Communacopia + Technology Conference in San Francisco, CA on Thursday, September 15, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time). A live webcast of the … [Read more…]

Executive changes announced in support of the Corporation Growth Phase: Ms. Sybil Dahan takes on the role of Devonian’s Chairperson of the Board of Directors Mr. Pierre Montanaro takes on the role of Devonian’s President & CEO. Dr André P. Boulet takes on the role of Chief Scientific Officer (CSO). Restructuring of Devonian’s subsidiary Altius … [Read more…]